ANNX Stock Overview
A biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Annexin Pharmaceuticals AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.47 |
| 52 Week High | SEK 0.93 |
| 52 Week Low | SEK 0.20 |
| Beta | 1.06 |
| 11 Month Change | -5.62% |
| 3 Month Change | -23.45% |
| 1 Year Change | -38.96% |
| 33 Year Change | -62.70% |
| 5 Year Change | -82.59% |
| Change since IPO | -95.18% |
Recent News & Updates
Shareholder Returns
| ANNX | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | -4.1% | -6.8% | -2.1% |
| 1Y | -39.0% | 8.0% | 10.8% |
Return vs Industry: ANNX underperformed the Swedish Pharmaceuticals industry which returned 8% over the past year.
Return vs Market: ANNX underperformed the Swedish Market which returned 10.8% over the past year.
Price Volatility
| ANNX volatility | |
|---|---|
| ANNX Average Weekly Movement | 11.1% |
| Pharmaceuticals Industry Average Movement | 10.8% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: ANNX's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: ANNX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 4 | Anders Haegerstrand | www.annexinpharma.com/sv |
Annexin Pharmaceuticals AB (publ), a biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein. The company offers Annexin A5 to protect and repair blood vessels and counteract inflammation.
Annexin Pharmaceuticals AB (publ) Fundamentals Summary
| ANNX fundamental statistics | |
|---|---|
| Market cap | SEK 254.76m |
| Earnings (TTM) | -SEK 52.45m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.8x
P/E RatioIs ANNX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANNX income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 52.45m |
| Earnings | -SEK 52.45m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.098 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ANNX perform over the long term?
See historical performance and comparison